Monkeypox infection elicits strong antibody and B cell response against A35R and H3L antigens
Ron Yefet,
Nadav Friedel,
Hadas Tamir,
Ksenia Polonsky,
Michael Mor,
Lilach Cherry-Mimran,
Eyal Taleb,
David Hagin,
Eli Sprecher,
Tomer Israely,
Natalia T. Freund
Affiliations
Ron Yefet
Department of Microbiology and Clinical Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Nadav Friedel
Division of Dermatology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel
Hadas Tamir
Department of Infectious Diseases, The Israel Institute for Biological Research, Ness Ziona, Israel
Ksenia Polonsky
Department of Microbiology and Clinical Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Edmond J. Safra Center for Bioinformatics at Tel-Aviv University, Tel Aviv, Israel
Michael Mor
Department of Microbiology and Clinical Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Lilach Cherry-Mimran
Department of Infectious Diseases, The Israel Institute for Biological Research, Ness Ziona, Israel
Eyal Taleb
Division of Dermatology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel
David Hagin
Department of Immunology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Eli Sprecher
Division of Dermatology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Department of Human Molecular Genetics and Biochemistry, Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel
Tomer Israely
Department of Infectious Diseases, The Israel Institute for Biological Research, Ness Ziona, Israel
Natalia T. Freund
Department of Microbiology and Clinical Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Corresponding author
Summary: Monkeypox virus (MPXV) resides in two forms; mature and enveloped, and depending on it, distinct proteins are displayed on the viral surface. Here, we expressed two MPXV antigens from the mature, and one from the enveloped form, and tested their reactivity to sera of 11 MPXV recoverees while comparing to sera from recently and past vaccinated individuals. 8 out of 11 recoverees exhibited detectable neutralization levels against Vaccinia Lister. Sera from all recoverees bound strongly to A35R and H3L antigens. Moreover, the responses to A35R were significantly higher within the recoverees compared to both recently and past vaccinated donors. Lastly, A35R- and H3L-specific IgG+ B cells ranging from 0.03-0.46% and 0.11–0.36%, respectively, were detected in all recoverees (A35R), and in 9 out of 11 recoverees (H3L). Therefore, A35R and H3L represent MPXV immune targets and could be used in a heat-inactivated serological ELISA for the identification of recent MPXV infection.